Clinical Trial Update: HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for HPB-092 in relapsed and refractory acute myeloid leukemia, with the study listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• HPB-092

Snippet

Sponsor: Hangzhou Polymed Biopharmaceuticals, Inc. | Conditions: Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | Phase 1 | Status: NOT_YET_RECRUITING